Iovance Biotherapeutics updated its corporate presentation on October 5, 2026, revealing an increase in full-year 2026 revenue guidance to a range of $410 million to $420 million. This midpoint represents approximately $55 million, or roughly 15%, above the previous guidance range of $350 million to $370 million. The company also highlighted that second-quarter 2026 revenue exceeded its prior guidance by more than 10%. Iovance Biotherapeutics is a biotechnology company specializing in tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors.
